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Abstract Glycosphingolipids (GSLs) are a group of plasma-
membrane lipids notable for their extremely diverse glycan
head groups. The metabolic pathways for GSLs, including the
identity of the biosynthetic enzymes needed for synthesis of
their glycans, are now well understood. Many of their cellular
functions, which include plasma-membrane organization, reg-
ulation of cell signaling, endocytosis, and serving as binding
sites for pathogens and endogenous receptors, have also been
established. However, an understanding of their functions
in vivo had been lagging. Studies employing genetic manipu-
lations of the GSL synthesis pathways in mice have been used
to systematically reduce the large numbers and complexity of
GSL glycan structures, allowing the in vivo functions of GSLs
to be revealed from analysis of the resulting phenotypes.
Findings from these studies have produced a clearer picture
of the role of GSLs in mammalian physiology, which is the
topic of this review.
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Introduction
Glycosphingolipids (GSLs) constitute the most structurally
diverse subgroup of the sphingolipid family [1]. They contain
a hydrophilic glycan head group, consisting of one or more
oligosaccharide residues, and a hydrophobic ceramide anchor.
The GSLs reside primarily in plasma membranes, with the
ceramide anchor embedded in the lipid bilayer and the
oligosaccharide head group exposed to the extracellular
environment.
Dedicated GSL synthesis is initiated by the transfer of either
a glucose or a galactose moiety in β-linkage to the position 1
hydroxyl group of ceramide, resulting in the formation of
glucosylceramide (GlcCer) or galactosylceramide (GalCer)
(Fig. 1). The subsequent addition of galactose to GlcCer forms
lactosylceramide (LacCer). LacCer serves as a hub in the
pathway in which the substrate can be diverted into one of
several pathways by the actions of distinct glycosyltransferases
that lead to the formation of GSL subfamilies, with distinct core
or root carbohydrate sequences, known as GSL series (Fig. 1).
GalCer is also modified similarly subsequent to its synthesis,
but the complexity the GalCer-based GSLs (gala series) is far
less than that of the GlcCer-based GSLs.
When the oligosaccharide head groups of GSLs are mod-
ified by the addition of one or more sialic acids (usuallyα-2,3-
or α-2,8-linked N-acetylneuraminic acid), the GSLs produced
are termed gangliosides [2] (Fig. 1). GSL head groups can also
be modified by sulfate and are called sulfatides. All told, the
number of GSLs with distinct oligosaccharide structures has
been estimated to be greater than 400 [1].
Some of the mechanisms by which GSLs exert their func-
tions at a cellular and molecular level have been well defined
[1, 3–5]. Their most basic function is as building blocks of the
plasma membrane. In this case, GSLs, due to their ability to
form liquid-ordered phases in membranes, can drive the for-
mation of functionally and structurally discrete plasma-
membrane domains [3, 6]. GSLs, through their glycan head
groups, can act as binding sites for pathogens and toxins [7]
and, in a similar manner, for endogenous molecules, such as
myelin-associated glycoprotein, to facilitate cell-to-cell inter-
actions [8]. Through lateral interactions with membrane pro-
teins, such as the insulin and epidermal growth factor recep-
tors, GSLs can modulate the strength of receptor-mediated
signaling pathways [9, 10]. Finally, they can function
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dynamically in the endocytic pathway by participating in the
internalization of diverse cargoes [11].
This review focuses on GSL functions at a physiological
level in mammals. A major challenge in this area has been to
uncover their actions in the midst of the enormous structural
variation of the glycan head groups that may be a source of the
GSLs’ functional diversity. This hurdle has been overcome by
the systematic elimination of diverse GSL glycan structural
groups in genetic deletion studies. Through the targeting of
specific glycosyltransferases and other modifying enzymes,
either singly or in combination and in a tissue-specific fash-
ion—in effect simplifying the complexity of the GSLs—their
in vivo functions have been elucidated from analysis of the
resulting phenotypes.
Global deletion of glucosylceramide-derived GSLs (Ugcg
knockout)
UDP-glucose:ceramide glycosyltranferase (GlcCer synthase)
is the rate-limiting enzyme for GlcCer-based GSL biosynthe-
sis. It is encoded by the Ugcg gene in the mouse [12, 13].
GlcCer synthase catalyzes the synthesis of GlcCer by the
transfer of a glucose residue from UDP-glucose to ceramide.
Once formed, GlcCer is modified by glycosyltransferases in
the Golgi, ultimately giving rise to hundreds of more complex
GSLs [1] (see Fig. 1).
Global deletion of the Ugcg gene in mice, which con-
sequently eliminates all GlcCer-based GSLs, caused early
embryonic lethality [14]. Ugcg knockout (KO) embryos
developed until gastrulation at E6.5, forming the ectoder-
mal, endodermal, and mesodermal layers, and with em-
bryonic patterning. A day later, mutant embryos showed
retarded growth and extensive apoptosis, primarily in the
ectodermal layer, and were subsequently resorbed. These
results are a vivid demonstration that GlcCer-based GSL
synthesis is an absolute requirement for mammalian em-
bryonic development [15].
Pan nervous-system deletion of GlcCer GSLs
GSLs, primarily in the form of gangliosides, are abundant-
ly expressed in the nervous system, making up about 10 %
of the total lipids and suggesting a vital role during the
formation of and/or function in these tissues [5, 16]. In
order to determine the importance of these lipids during
the formation of a functional nervous system, two inde-
pendently derived lines of mice lacking Ugcg in neuronal
and glia cells were established by combining a floxed
Ugcg allele and a Cre recombinase transgene under the
control of the pan nervous system rat nestin promoter and
enhancer (NesCre) [17, 18]. NesCre-Ugcg KO mice did
not show evidence of embryonic lethality and appeared
normal at birth. However, they developed neurologic
Fig. 1 GSL synthesis pathways.
Genes that have been targeted are
in the rounded boxes. The major
mouse phenotypes caused by
genetic blocks in the GSL
pathways are indicated in red text.
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abnormalities over time. The severity of the phenotypes in
the two lines was different and appeared to be related to
the level of residual Ugcg expression found in the respec-
tive NesCre-Ugcg KO brains. The mouse line produced by
Jennemann et al. [18], in which the levels of Ugcg mRNA
and gangliosides in brain were nearly completely elimi-
nated, died by 3 weeks of age, and displayed very severe
neurological symptoms, including ataxia, reduced axonal
branching of neurons, and disturbed myelination of pe-
ripheral nerves. The line generated in the Proia laboratory
[17] showed residual Ugcg expression, a significant, but
incomplete reduction of ganglioside levels in the brain, as
well as a longer life span. These mice also displayed
abnormal gait, along with a progressive loss of Purkinje
cells [18].
These reports show that GlcCer-based GSL synthesis is
expendable for embryonic development of the nervous sys-
tem, but is required for its proper development, stability, and
function after birth.
Neuronal-specific deletion of GlcCer-based GSLs
The deletion of Ugcg specifically in neuronal cells was
achieved by generating floxed Ugcg mice expressing the
Cre recombinase gene under the L7 promoter only in Purkinje
cells [19]. These mice, showed Purkinje cell degeneration at
about 3–4 months of age, which was characterized by axon
swelling and accumulation of axonal transport cargos prior to
Purkinje cell loss. Significant abnormal myelination was pres-
ent, as were detached paranodal junctions (the attachment sites
of neuronal axons and oligodendrocytes), implying that the
neuronally synthesized GSLs were critical for these axonal-
glial interactions.
In a separate study, Ugcg was deleted after birth using an
inducible Cre recombinase (Cre-ERT2) under the control of
the neuronal calcium/calmodulin-dependent kinase II α pro-
moter (CamK). In these mice, expression of the Ugcg gene
was deleted from the neurons of the forebrain, including the
hypothalamic nuclei, which are involved in energy homeosta-
sis regulation. CamKCre-ERT2-Ugcg KO mice showed pro-
gressive body-weight gain, hypometabolism, and hypother-
mia. This phenotype could be reversed by virus-mediated
expression of Ugcg in the arcuate nucleus (Arc) of the hypo-
thalamus, a key regulator of feeding and metabolism. Leptin
signaling, which is essential for metabolic homeostasis, was
impaired in Arc neurons from the CamKCre-ERT2-Ugcg KO
mice. The basis for the impaired leptin responsiveness in the
Arc neurons appeared to be due to a lack of GlcCer-based
gangliosides, which normally directly associate with the leptin
receptor on the plasma membrane and promote leptin respon-
siveness [20].
Oligodendrocyte-specific deletion of GlcCer-based GSLs
Ugcgwas deleted specifically in oligodendrocytes by crossing
floxed Ugcg mice with a line expressing Cre recombinase
under the control of the myelin-associated enzyme 2′, 3′ cyclic
nucleotide 3′ phosphodiesterase (CnpCre) [21]. The resulting
oligodendrocyte-specific CnpCre-Ugcg KO mice did not
show any myelin abnormalities, indicating that oligodendro-
cyte GlcCer-derivedGSLs, unlike those produced by neuronal
cells, are not essential for myelin structure and stabilization.
Keratinocyte-specific deletion of Glc-Cer based GSLs
Keratinocytes produce large amounts of GSLs, mainly
GlcCer, accounting for almost 4 % of the total lipid content
in the epidermis, which is packed into lamellar bodies and
delivered to the stratum corneum for further processing to
generate ceramide [22, 23]. Floxed Ugcg mice were crossed
with a keratin K14 promoter-driven Cre line to produce mice
lacking Ugcg expression in keratinocytes (K14Cre-Ugcg KO
mice) [24].K14Cre-UgcgKO pups showed profound desqua-
mation and epidermal dehydration and died at about 4 days of
age. Their skin showed broadened epidermal layers, abnormal
lamellar bodies, keratinocyte apoptosis, and inflammation.
When epidermal deletion was induced after birth using a
tamoxifen-inducible (TAM) K14Cre transgene to bypass the
early lethality, TAM-K14Cre-Ugcg KO mice showed epider-
mal abnormalities similar to the K14Cre-Ugcg KO mice [25].
These studies supported the conclusion that Ugcg expression
is essential for the formation of a functional epidermal perme-
ability barrier through the generation of GlcCer, a precursor
for the formation of ceramide in the skin.
Liver-specific deletion of Glc-Cer based GSLs
Liver is a central site controlling sphingolipid metabolism
[26]. A liver-specific knockout of Ugcg was generated by
crossing floxed Ugcg mice with mice expressing Cre
recombinase under the control of the albumin promoter
(AlbCre-Ugcg mice) [27]. The mice had greatly reduced
GSL levels in liver and plasma, pinpointing liver as the major
source of plasma GSLs. No other phenotype was detected in
the AlbCre-Ugcg mice, even after challenge with a high-fat
diet, arguing against a vital role of hepatic GlcCer synthesis in
glucose control, liver steatosis, or cholesterol metabolism.
Enterocyte-specific deletion of Glc-Cer based GSLs
GSLs are highly concentrated in the columnar epithelial cells
that form the villi in the intestine, known as enterocytes.
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Enterocyte-specific Ugcg-deficient mice were generated by
crossing floxed Ugcg mice with mice expressing Cre
recombinase under the control of the villin promoter induced
either in the embryo (using VilCre-expressing mice) or during
adult life (using VilCre-ERT2-expressing mice) [28]. GlcCer-
derived GSLs were profoundly absent in the intestines of the
VilCre-Ugcg pups. Although undistinguishable from control
littermates at birth, VilCre-Ugcg pups did not gain weight and
died by postnatal day 8. VilCre-Ugcg pups showed normal
polarization of the enterocytes, but had abnormal mucosal
villi, decreased fat deposits, and a severe decrease in the
ability of enterocytes to uptake lipid. Inducible VilCre-ERT2-
Ugcg mice showed an almost complete absence of intestinal
GSLs 4 days after deletion induction, which was concomitant
with significant structural alterations in the villous epithelia.
These mice also had decreased body weight and reduced lipid
absorption by the enterocytes. These findings demonstrate
that GlcCer-derived GSLs are necessary for proper intestinal
function.
Deletion of lactosylceramide-based GSLs: B4galt5 KO
LacCer is synthesized in the Golgi lumen by LacCer synthase
(β-1,4-galactosyltransferase 5) via the transfer of galactose
from UDP-galactose to GlcCer. B4galt5 null mice were gen-
erated by conventional gene targeting [29] and through a
large-scale gene-trap project [30]. Both gene targeting strate-
gies led to lethality in utero. The B4galt5−/− embryos appeared
normal until E6.5, showed retarded growth by E7.5, and died
around E10.5. B4galt5−/− embryos showed bleeding in the
extra-embryonic tissues at E7.5 [29]. The early lethality of the
B4galt5−/− embryos could be rescued by wild-type extra-em-
bryonic tissues; however, these embryos did not develop past
E18.5, indicating that B4galt5 has a direct role in later embry-
onic development within the embryo proper [29].
Deletion of ganglio-series GSLs: B4galnt1 KO
G M 2 / G D 2 s y n t h a s e ( β - 1 , 4 - N - a c e t y l -
galactosaminyltransferase), which is encoded by B4galnt1,
transfers N-acetylgalactosamine to LacCer to initiate the syn-
thesis of ganglio-series GSLs, including the sialic acid-
containing gangliosides (Fig. 1) [31]. The genetic deletion of
B4galnt1 resulted in mice lacking the normal complement of
complex gangliosides and instead expressing predominantly
GM3 and GD3 (Fig. 1) [32, 33]. Despite the drastic change in
the ganglioside composition, B4galnt1−/− mice unexpectedly
underwent largely normal brain development.
However, B4galnt1−/− mice were found to display de-
creased myelination of central axons, as well as demyelination
of peripheral nerves [33]. As a consequence, axon
degeneration occurred within the central nervous system,
leading to impaired motor function [33, 34]. Nodes of Ranvier
showed abnormal structures in B4galnt1−/− mice, causing
defects in conduction velocity of the motor nerves [33]. One
of the functions of gangliosides within the axonal membrane
is as ligands for MAG displayed on oligodendrocytes to
promote axon-glia interactions [35]. Indeed, B4Galnt1 −/−
mice showed a decrease in MAG expression in the brain
[33] and MAG deficient mice displayed a similar phenotype
as B4Galnt1 −/− mice [35]. These findings suggest that the
lack of complex ganglioside-MAG interactions was a cause of
the B4Galnt1 null phenotype and demonstrate an essential
role in myelin stabilization. Another independently generated
B4galnt1−/− mouse line showed subtle defects in the nervous
system, with a slight reduction in the neural conduction ve-
locity and a defect in cognitive performance [36]. These
findings indicate an essential role for gangliosides in myelin
stabilization and for proper neuronal function.
The discovery that B4galnt1−/− male mice are infertile
revealed an important function of complex gangliosides in
spermatogenesis [32, 33, 37]. The absence in the B4galnt1−/−
male mice of a novel class of fucosylated, polyunsaturated
GSLs with highly elongated fatty acids typically present in
male germ cells was linked to their infertility [38].
Deletion of a-series gangliosides: St3gal5 KO
GM3 synthase (CMP-sialic acid:lactosylceramide α-2,3-
sialyltransferase) is encoded by St3gal5. The enzyme transfers
sialic acid to LacCer to produce GM3, the simplest of the
sialic acid-containing GlcCer-based gangliosides and a pre-
cursor for complex gangliosides [2].
St3gal5-deficient mice had normal life span [39]. Analysis
of their ganglioside content demonstrated the absence of GM3
and all GM3-derived gangliosides from the a- and b- series
(Fig. 1), which are the major gangliosides in the brain [2].
GM3 synthase deletion increased insulin sensitivity; that is,
St3gal5−/− mice had enhanced phosphorylation of the insulin
receptor in skeletal muscle after insulin binding, and better
responses in glucose- and insulin-tolerance tests. Accordingly,
they were also protected from insulin resistance development
after a high-fat diet regimen [39].
Diabetic diet-induced obese St3gal5−/− mice were also
found to be protected from a wound-healing defect. Wound
healing generally involves proliferation and migration of
keratinocytes, which are both mediated by the insulin receptor
and insulin growth factor-1 receptor. Because diabetic obese
St3gal5−/− mice indeed had activated insulin receptor and
insulin growth factor-1 receptor signaling, particularly in the
presence of high glucose, the wound-healing defects observed
in wild-type diabetic obese mice were obviated [40].
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An independently generated line of St3gal5−/−mice exhib-
ited complete hearing loss [41]. The St3gal5−/− mice showed
degeneration and disappearance of the organ of Corti, which is
the hearing sensor in the cochlea. These results suggest that
GM3 synthesis is essential for the early maturation of the
cochlea and that it is important in development of the auditory
system.
Deletion of b-series gangliosides: St8sia1 KO
GD3, the precursor of the di-sialo b-series gangliosides
(Fig. 1), is generated by the addition of sialic acid to GM3
by GD3 synthase (CMP-sialic acid: GM3 α-2,8-
sialyltransferase), encoded by the St8sia1 gene. Despite the
absence of the normally prominent b-series gangliosides in the
brain, the deletion of the St8sia1 gene did not cause apparent
developmental abnormalities in the nervous system [42, 43].
Adult St8sia1−/− mice were found to be viable and grossly
normal.
A second independently derived line of St8sia1−/−
mice exhibited reduced regeneration capacity of the hy-
poglossal nerve, showing fewer surviving neurons after
resection of the nerve [42]. In addition, St8sia1−/− mice
displayed increased sensory responses to thermal and
mechanical stimuli and decreased response to subcutane-
ous formalin injection, which is a measure of clinical
pain, suggesting GD3-based gangliosides mediate trans-
mission of pain and might be important in the sensory
system [44].
“GM3-only” mice: St8sia1/B4galnt1 double knockout
St8sia1/B4galnt1 double knockout (DKO) mice were gener-
ated by crossing animals carrying the St8sia1 and B4galnt1
null alleles [43]. Homozygous DKO mice were viable and
expressed only GM3 as a GlcCer-based ganglioside in their
brains. Strikingly, these DKO mice were extremely suscepti-
ble to sound-induced lethal seizures, and most died by
3 months of age [43]. A separate DKO line did not display
any seizure-related phenotype, although these mice had de-
creased weight, motor dysfunction, low fear stress, and re-
duced sensory responses due to peripheral nerve degeneration
[45]. These DKO mice also acquired severe skin lesions,
possibly caused by the reduced sensory function [46]. These
findings show that complex ganglioside expression is essen-
tial to maintain the normal function of the central and periph-
eral nervous systems, and that these functions of complex
ganglioside structures cannot be replaced by the expression
of the simple ganglioside GM3.
“Ganglioside-less” mice: St3gal5/B4galnt1 DKO
Phenotypes seen in B4galnt1−/− or St8sia1/B4galnt1 DKO
mice demonstrated that expression of even simple ganglio-
sides such as GM3 and GD3 were sufficient for the develop-
ment of a functioning nervous system, although with some
defects. To answer if gangliosides were truly essential for
nervous-system development, the elimination of all GlcCer-
based gangliosides was achieved by crossing mice carrying
null mutations in the St3gal5 and B4galnt1 genes (Fig. 1) to
create St3gal5/B4galnt1 DKO mice. These DKO mice were
initially viable but soon developed hindlimb weakness,
tremors, and ataxia; most died within 3 months of birth [47].
As expected, and in accordance with the proposed biosynthet-
ic pathway, these DKO mice were unable to synthesize any
gangliosides of the ganglio-series and instead accumulated
LacCer. DKO mice showed severe neurodegenerative symp-
toms, including a smaller brain and prominent areas of
vacuolization in the spinal cord and brain white matter. Mye-
linated axons were degenerated in these mice, and showed
abnormalities of paranodal junctions at the nodes of Ranvier,
which suggests impairment of the axon-glia interactions. The-
se findings indicate that GlcCer-based gangliosides are not
required for early neural differentiation or morphogenesis of
the brain, but are critical for promoting the formation or
stabilization of functional axon-glia interactions. The absence
of gangliosides ultimately leads to axonal degeneration.
Deletion of the globo-series of GSLs: A4galt KO
Gb3 synthase (α-1,4-galactosyltransferase), which is encoded
by the A4galt gene, is responsible for the synthesis of Gb3
(Galα1–4Galβ1–4Glcβ1Cer) by the addition of an α-1,4-
linked galactose to LacCer, initiating the production of the
globo-series of GSLs. A4galt−/− mice were deficient in Gb3
and other globo-series GSLs [48]. These KO mice appeared
normal and lacked any obvious phenotype. Gb3 has been
reported to be a ligand for the bacterial endotoxins Shiga-
like and verotoxins, which are associated with hemorrhagic
colitis and hemolytic uremic syndrome. Accordingly,A4galt−/−
mice were found to be protected from the effect of these toxins,
clearly demonstrating that globo-series GSLs are endogenous
ligands for these toxins [48].
Deletion of the isoglobo-series of GSLs: A3galt2 KO
iGb3 synthase (α-1,3-galactosyltransferase), which is
encoded by the A3galt2 gene, initiates the formation of the
isoglobo-series of GSLs with the synthesis of iGb3 (Galα1–
3Galβ1–4Glcβ1Cer) from LacCer by the addition of an α-
1,3-linked galactose (Fig. 1). Deletion of the A3galt2 gene
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eliminated iGb3 and the other isoglobo-series GSLs derived
from iGb3 [49]. Similar to the globo-series null mice,
A3galt2−/− mice did not display any obvious phenotype. Al-
though iGb3 was thought to be an endogenous ligand for the
invariant Vα14-expressing natural killer T (NKT) cells, there-
by regulating their development in thymus [50], A3galt2−/−
mice showed normal NKT numbers and function [49]. This
result suggests that this GSL species may not be a relevant
ligand for thymic NKT cells in vivo.
Deletion of the lacto/neolacto-series of GSLs: B3gnt5 KO
Lc3 synthase (β-1,3-N-acetylglucosaminyltransferases 5),
which is encoded by B3gnt5, produces Lc3 (GlcNAcβ1–
3Galβ1–4Glcβ1Cer), initiating the lacto/neolacto-series of
GSLs (Fig. 1), with the transfer of N-acetylglucosamine to
LacCer. Three independent groups have reported targeting the
B3gnt5 gene in mice, with different outcomes. Genetic dele-
tion of the B3gnt5 gene in mice by Biellmann et al. [51]
caused embryonic lethality at the preimplantation stage, pos-
sibly due to defects in cell-cell adhesion that contribute to
embryo compaction and implantation. The line generated by
Togayachi et al. produced viable B3gnt5−/− mice that showed
a defect in B-cell signaling due to abnormal raft formation
[52]. Kuan et al. [53] developed B3gnt5−/− mice by two
different strategies. They reported thatB3gnt5−/−mice showed
splenomegaly and enlarged lymph nodes, and had shorter,
variable life spans. They also had lower B-cell numbers,
exhibited hair loss, were obese, and had reproductive defects.
The reasons for the discrepancies among the phenotypes of
the B3gnt5−/−mouse lines in the three reports are not apparent.
Deletion of GalCer-based GSLs: Ugt8a KO
Galactosylceramide synthase (UDP-galactose:ceramide
galactosyltransferase), encoded by the Ugt8a gene, catalyzes
the formation of GalCer by the attachment of a galactose
residue to the ceramide backbone (Fig. 1) [13, 54]. GalCer
and its sulfated derivative, GalCer-sulfate or SM4 (Fig. 1), are
greatly enriched in the myelin sheath that covers axons,
representing nearly 30 % of the total lipid [55]. Two indepen-
dent groups generated Ugt8a-deficient mouse lines through
conventional targeting of the Ugt8a gene [55, 56]. Homozy-
gous Ugt8a−/− mice were initially viable, but were small and
had shortened life spans. They also exhibited tremors, loss of
locomotor activity, and disruption of nerve conduction. Sur-
prisingly, Ugt8a−/− mice were able to form myelin sheaths
lacking GalCer and its derivative SM4, but instead containing
GlcCer, a GSL not normally abundant in myelin. The myelin
structure of the Ugt8a−/− mice initially appeared normal, ex-
cept for slightly thinner sheaths in some areas of the spinal
cord. Later, the myelin became unstable and degenerated.
Together, these studies demonstrated that GalCer synthesis is
needed for long-term maintenance of the structure and func-
tion of the myelin.
Interestingly, restoration of oligodendrocyte Ugt8a expres-
sion was able to correct the aberrant phenotype in Ugt8a−/−
mice, including normalizing life span, behavior, and myelin
structure [57]. These results indicate that the loss of Ugt8a in
oligodendrocytes was responsible for the myelin defects and
altered behavior described for Ugt8a−/− mice.
Deletion of sulfated GalCer: Gal3st1 KO
Gal3st1 encodes for the glycolipid-specific GalCer
sulfotransferase [58], which adds a sulfate group to GalCer
to form SM4 which is incorporated into myelin (Fig. 1)
[59–61]. To determine the role of sulfated GSL in vivo, mice
with a deletion of Gal3st1 were generated [62]. Gal3st1−/−
mice were normal at birth, but as they aged they developed
neurological symptoms (exhibiting as weakness of the
hindlimbs, tremors, and progressive ataxia) However, these
mice were able to survive for more than 1 year. These mice
lacked SM4, but still expressed GalCer in the brain [62]. Their
axons were myelinated, but the myelin showed vacuolation,
and exhibited defective paranodal junctions and abnormal ion-
channel localization along the axonmembrane [62–65]. These
results demonstrate the important role of sulfated GalCer in
the formation interactions between axons and glia.
Fig. 2 In vivo GSL functions revealed by whole body and conditional
gene deletion studies in mice
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Sulfated GSLs are highly enriched in the kidney, especial-
ly at the distal nephron segments and in the renal medulla [61,
66, 67]. To determine the role of sulfated GSLs specifically in
kidney, Gal3st1 was deleted via renal epithelia-specific ge-
netic disruption either individually to eliminate sulfated
GSLs, or in combination with Ugcg to further remove possi-
ble compensatory anionic GlcCer-based GSLs, Mice carrying
floxed Gal3st1 and Ugcg alleles were crossed with mice
expressing the Cre recombinase gene under the control of
the tubular epithelial cell-specific paired box gene 8 promoter
(Pax8Cre) [68]. Kidneys from single (KO) and double KO
(DKO) mice lacked the predicted sulfated GSL species in the
kidney and showed generally normal kidney morphology.
However, the Pax8Cre-Gal3st1 KO and Pax8Cre-Gal3st1/
Ugcg DKO mice both showed significantly lower pH and
less ammonium excretion in the urine. When fed an acidic
diet, the Gal3st1−/− mice exhibited decreased ammonium
accumulation in the papilla, and chronic hyperchloremic ac-
idosis. The results are consistent with the notion that sulfated
GSLs in the kidney act as counterions of interstitial NH4+,
allowing its accumulation in the kidney papilla and enabling
sufficient renal excretion of protons to maintain a proper
blood pH [68]. The results show that sulfated GSLs are
critical for physiologic acid–base homeostasis.
Conclusions and perspectives
During the period of time since the description of the first
knockout mice targeting enzymes in the GSL synthesis path-
way in 1996 [32, 55], we have seen a striking increase in our
understanding of the roles of GSLs in physiology (Fig. 2). We
have learned that they are not only fundamentally important
for embryonic development, but also have key tissue-specific
functions, including formation of the skin permeability barrier,
acid handling in the kidney for maintenance of acid–base
homeostasis, and key nervous-system functions (including in
neuron-glial interaction to maintain myelin stability and neu-
ronal control of appetite). It is likely that we have only
scratched the surface of GSL functions, given the existence
of hundreds of different GSL structures and that we only
understand the function of a relatively very few. Furthermore,
our knowledge of how GSLs act in human disease is only in
its infancy. While lysosomal storage diseases in which GSL
degradation pathways are disrupted have been known for
many years [69], only recently have genetic diseases involv-
ing the GSL synthesis pathways been described [70–73]. A
new challenge is to build on current insights into normal GSL
functions (Fig. 2) to understand how GSLs play a role in the
pathogenesis of other disorders. In this vein, significant prog-
ress is already being made in a number of human diseases
[74–76]. These insights will eventually lead to therapeutics
aimed at targeting specific GSL pathways for the treatment of
these disorders.
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